drugset
drugset / Trial / NCT05173883

A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population

NCT05173883 ↗

Phase 1 Completed 48 enrolled Cutia Therapeutics (Wuxi) Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, Part I/2/3/4 Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of a single subcutaneous injection of CU-20401 in healthy Chinese population, and to recommend an appropriate dose for subsequent clinical studies.

Timeline

Start
2021-12-20
Primary completion
2023-11-02
Completion
2023-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CU-20401 Unknown 0.04 mg Subcutaneous
Subject CU-20401 Unknown 0.075 mg Subcutaneous
Subject CU-20401 Unknown 0.1 mg Subcutaneous
Subject CU-20401 Unknown 0.12 mg Subcutaneous
Subject CU-20401 Unknown 0.15 mg Subcutaneous

Indications

No indication recorded.